Published in Ecancermedicalscience on May 11, 2010
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst (2003) 7.06
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol (1998) 2.96
Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood (2000) 2.87
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood (2006) 2.51
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol (2007) 2.14
Thalidomide as initial therapy for early-stage myeloma. Leukemia (2003) 2.02
Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol (1994) 2.01
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1994) 1.49
Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia (2001) 1.36
Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. Eur J Haematol (1993) 1.32
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma (2009) 1.00
Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol (2005) 0.98
A prognostic index for multiple myeloma. Br J Cancer (1996) 0.90
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag (2009) 0.81
Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience. Semin Hematol (2001) 0.77
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol (2000) 2.00
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res (2001) 1.76
Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. Ann Oncol (2009) 1.67
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res (2000) 1.33
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol (2006) 1.22
Two-stage plans for patient accrual in phase II cancer clinical trials. Cancer Treat Rep (1980) 1.19
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol (2007) 1.14
Malignant mesothelioma of the tunica vaginalis testis. J Clin Oncol (1984) 0.99
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol (1995) 0.98
Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs (1994) 0.92
Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res (2010) 0.92
Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications. Ann Oncol (1994) 0.91
Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. Ann Oncol (2006) 0.87
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer. Ann Oncol (2012) 0.85
Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol (1985) 0.85
Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers. Ecancermedicalscience (2008) 0.84
Immunological profile of breast cancer patients in early or advanced disease. Experientia (1979) 0.83
Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys (1997) 0.83
Mucinous cancer of the appendix: challenges in diagnosis and treatment. J Chemother (2007) 0.83
A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. Cancer (2001) 0.83
MDR1 gene expression in primary and advanced breast cancer. Lab Invest (1999) 0.83
[Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial]. Nouv Presse Med (1979) 0.83
Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone. Ann Oncol (2008) 0.83
Phase II trial of carboplatin or iproplatin in cervical cancer. Cancer Chemother Pharmacol (1991) 0.81
Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecol Oncol (2006) 0.81
Treatment of primary breast cancer. Summary of the National Institutes of Health Consensus Development Conference. JAMA (1980) 0.81
Advanced ovarian cancer: three-year results of a 6-8 month, 2-drug cisplatin-containing regimen. Eur J Cancer Clin Oncol (1987) 0.80
Biological modification of protracted infusion of 5-fluorouracil with weekly leucovorin. A dose seeking clinical trial for patients with disseminated gastrointestinal cancers. Cancer Chemother Pharmacol (1990) 0.80
Malignancies in the acquired immunodeficiency syndrome. Curr Probl Cancer (1987) 0.79
High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol (1998) 0.79
Low doses of dexamethasone protect against paclitaxel (Taxol)-related hypersensitivity reactions following cycle 1. Ann Oncol (1994) 0.78
Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. Int J Gynecol Cancer (2007) 0.78
Taxanes in adjuvant and neoadjuvant therapies for breast cancer. Oncology (Williston Park) (1998) 0.78
Preclinical pharmacokinetics and stability of isophosphoramide mustard. Cancer Chemother Pharmacol (1994) 0.78
Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies. Cancer Chemother Pharmacol (1990) 0.78
Single-dose dacarbazine and dactinomycin in advanced malignant melanoma. Cancer Treat Rep (1985) 0.77
The "other" asparaginase. Med Pediatr Oncol (1976) 0.77
Acid phosphatase levels in bone marrow: value in detecting early bone metastasis from carcinoma of the prostate. J Urol (1970) 0.76
A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity. Cancer Chemother Pharmacol (2013) 0.76
Hexamethylmelamine in platinum-resistant ovarian cancer: how active? Gynecol Oncol (1992) 0.75
Phase I clinical trial of isophosphamide (NSC-109724). Cancer Chemother Rep (1975) 0.75
Endocrine-responsive breast cancer: a 28-year Odyssey. Ecancermedicalscience (2011) 0.75
Paraneoplastic hypercalcemia in clear cell ovarian adenocarcinoma. Ecancermedicalscience (2012) 0.75
Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo. Ecancermedicalscience (2008) 0.75
BRCA-deficient animal models and cisplatin resistance. Ann Oncol (2009) 0.75
Familial breast cancer screening: ethical and social implications. Ann Oncol (2004) 0.75
A screening and prevention programme serving an ethnically diverse population of women at high risk of developing breast and/or ovarian cancer. Ecancermedicalscience (2009) 0.75
Search for the optimal treatment of ovarian cancer: heavy metals, "belly baths," and ... yew trees. J Clin Oncol (1992) 0.75
Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst (2001) 0.75
Estramustine potentiates taxane in prostate and refractory breast cancers. Oncology (Williston Park) (2001) 0.75
Adjuvant chemotherapy: correct advice. JAMA (1977) 0.75
High-dose chemotherapy and autologous bone marrow plus peripheral blood stem cell transplantation for patients with lymphoma or metastatic breast cancer: use of marker genes to investigate hematopoietic reconstitution in adults. Hum Gene Ther (1996) 0.75
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers? Clin Transl Oncol (2013) 0.75
Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): a phase I study with pharmacology. Cancer Chemother Pharmacol (1990) 0.75
Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's sarcoma (AIDS-KS). Invest New Drugs (1989) 0.75
Hereditary breast and ovarian cancer: risks and challenges. 10-12 September 2009: Bari, Italy. Introduction. Ann Oncol (2011) 0.75
Cancer and hypercalcemia of malignancy: a change in focus. Semin Oncol (1991) 0.75
[Availability and rational use of essential drugs in the treatment of cancer]. Bol Oficina Sanit Panam (1985) 0.75
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Invest New Drugs (1985) 0.75
Sequential methotrexate and 5-fluorouracil with bleomycin and cisplatin in the chemotherapy of advanced squamous cancer of the head and neck. Cancer (1986) 0.75
Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies. Gynecol Oncol (1996) 0.75
We're "fossilized" in the optimal use of the Ommaya reservoir. Oncology (Williston Park) (1990) 0.75
Combination chemotherapy containing semustine (MeCCNU) in patients with advanced colorectal cancer previously treated with 5-fluorouracil (5-Fu). Am J Clin Oncol (1983) 0.75
Doxorubicin and interferon: rationale and clinical experience. Cancer Treat Rev (1985) 0.75
The role of anthracyclines in the treatment of gastric cancer. Cancer Treat Rev (1985) 0.75
Phase II trial of Baker's antifol in patients with recurrent or inoperable head and neck cancer. Cancer Treat Rep (1986) 0.75
Treatment of advanced refractory lymphoma with teniposide and lomustine. Cancer Treat Rep (1987) 0.75
Saline MR peritoneography. AJR Am J Roentgenol (1996) 0.75
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors. Ann Oncol (2003) 0.75
Hereditary breast and ovarian cancer: lessening the burden. Ann Oncol (2013) 0.75
High-performance liquid chromatographic method for the determination of a novel thymidylate synthase inhibitor, AG 331, in human serum. J Chromatogr B Biomed Appl (1995) 0.75